Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 2, 2026, 7:57 PM EST

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1945–1968 of 21,220 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Immunity Disorders Clear all
Completed Not applicable Interventional

Shared Medical Appointments to Improve Outcomes in Adolescents With Type 1 Diabetes

NCT02547311
View directory record Official record
Conditions
Type 1 Diabetes
Interventions
Team Clinic
Behavioral
Lead sponsor
University of Colorado, Denver
Other
Eligibility
11 Years to 17 Years
Enrollment
318 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Jan 18, 2022 · Synced Nov 2, 2026, 7:57 PM EST
Completed No phase listed Observational

Long-term Observation of Patients With Early Rheumatoid Arthritis

NCT00240136
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
Not listed
Lead sponsor
University of California, Los Angeles
Other
Eligibility
18 Years and older
Enrollment
372 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1993 – 2020
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Nov 17, 2020 · Synced Nov 2, 2026, 7:57 PM EST
Not listed Phase 2 Interventional

Monoclonal Antibody Therapy in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma

NCT00014664
View directory record Official record
Conditions
Lymphoma
Interventions
apolizumab
Biological
Lead sponsor
PDL BioPharma, Inc.
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2000
U.S. locations
1
States / cities
Freemont, California
Source: ClinicalTrials.gov public record
Updated Dec 18, 2013 · Synced Nov 2, 2026, 7:57 PM EST
Completed Not applicable Interventional Results available

Use of Symbicort or Pulmicort to Treat Viral-mediated Asthma Exacerbations

NCT01218399
View directory record Official record
Conditions
Asthma
Interventions
Symbicort
Drug
Lead sponsor
Stanford University
Other
Eligibility
12 Years to 65 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Aug 18, 2017 · Synced Nov 2, 2026, 7:57 PM EST
Completed Phase 1 Interventional

A Phase 1 Study of SB1518 for the Treatment of Advanced Lymphoid Malignancies

NCT00741871
View directory record Official record
Conditions
Lymphoma, Malignant, Hodgkin's Lymphoma, B Cell Lymphoma
Interventions
SB1518
Drug
Lead sponsor
S*BIO
Industry
Eligibility
18 Years and older
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Apr 20, 2012 · Synced Nov 2, 2026, 7:57 PM EST
Completed No phase listed Observational Accepts healthy volunteers

At-Home Research Study for Patients With Autoimmune, Inflammatory, Genetic, Hematological, Infectious, Neurological, CNS, Oncological, Respiratory, Metabolic Conditions

NCT01931644
View directory record Official record
Conditions
All Diagnosed Health Conditions, ADD/ADHD, Alopecia Areata, Ankylosing Spondylitis, Asthma, Atopic Dermatitis Eczema, Beta Thalassemia, Bipolar Disorder, Breast Cancer, Celiac Disease, Cervical Cancer, Chronic Inflammatory Demyelinating Polyneuropathy, Chronic Kidney Diseases, Chronic Obstructive Pulmonary Disease, Colon Cancer, Colorectal Cancer, Crohn's Disease, Cystic Fibrosis, Depression, Diabetes Mellitus, Duchenne Muscular Dystrophy, Endometriosis, Epilepsy, Facioscapulohumeral Muscular Dystrophy, G6PD Deficiency, General Anxiety Disorder, Hepatitis B, Hereditary Hemorrhagic Telangiectasia, HIV/AIDS, Human Papilloma Virus, Huntington's Disease, Idiopathic Thrombocytopenic Purpura, Insomnia, Kidney Cancer, Leukemia, Lung Cancer, Lupus Nephritis, Lymphoma, Melanoma, Multiple Myeloma, Multiple Sclerosis, Myositis, Myotonic Dystrophy, Ovarian Cancer, Pancreatic Cancer, Parkinson's Disease, Polycystic Kidney Diseases, Prostate Cancer, Psoriasis, Psoriatic Arthritis, Rosacea, Scleroderma, Sickle Cell Anemia, Sickle Cell Trait, Sjogren's Syndrome, Skin Cancer, Spinal Muscular Atrophy, Systemic Lupus Erythematosus, Thrombotic Thrombocytopenic Purpura, Trisomy 21, Ulcerative Colitis
Interventions
Not listed
Lead sponsor
Sanguine Biosciences
Industry
Eligibility
18 Years to 100 Years
Enrollment
17,667 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2024
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Apr 18, 2024 · Synced Nov 2, 2026, 7:57 PM EST
Completed No phase listed Observational Accepts healthy volunteers

A Pilot Study to Evaluate the Efficacy of Refined Methods to Mitigate Indoor Allergens in North Carolina and Boston, Massachusetts Homes

NCT00344344
View directory record Official record
Conditions
Hypersensitivity
Interventions
Not listed
Lead sponsor
National Institute of Environmental Health Sciences (NIEHS)
NIH
Eligibility
21 Years and older
Enrollment
88 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2000 – 2006
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 2, 2017 · Synced Nov 2, 2026, 7:57 PM EST
Active, not recruiting Phase 1 Interventional

EBV CTLs Expressing CD30 Chimeric Receptors For CD 30+ Lymphoma

NCT01192464
View directory record Official record
Conditions
Hodgkin's Lymphoma, Non-Hodgkin's Lymphoma
Interventions
autologous CAR.CD30 EBV specific-CTLs
Drug
Lead sponsor
Baylor College of Medicine
Other
Eligibility
Not listed
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2033
U.S. locations
2
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Feb 6, 2026 · Synced Nov 2, 2026, 7:57 PM EST
Withdrawn Phase 1 Interventional

Retreatment With CTL019/CTL119

NCT04419909
View directory record Official record
Conditions
Lymphoma, B-Cell
Interventions
CD19 redirected autologous T cells (CTL019 or CTL119 cells)
Drug
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 22, 2026 · Synced Nov 2, 2026, 7:57 PM EST
Active, not recruiting No phase listed Observational

A Global Clinical Study Investigating the Safety and Effectiveness of Smith and Nephew's Porous Knee System in Patients Who Need a Total Knee Replacement Due to Degenerative Arthritis, Post-traumatic Arthritis or Inflammatory Arthritis

NCT05197036
View directory record Official record
Conditions
Osteoarthritis, Post-traumatic Arthritis, Rheumatoid Arthritis
Interventions
Total Knee Arthroplasty
Procedure
Lead sponsor
Smith & Nephew, Inc.
Industry
Eligibility
18 Years to 80 Years
Enrollment
299 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2033
U.S. locations
12
States / cities
Atlanta, Georgia • Boston, Massachusetts • Novi, Michigan + 8 more
Source: ClinicalTrials.gov public record
Updated Aug 11, 2026 · Synced Nov 2, 2026, 7:57 PM EST
Active, not recruiting Phase 2 Interventional Results available

Ipilimumab With or Without Nivolumab in Relapsed/Refractory cHL

NCT04938232
View directory record Official record
Conditions
Hodgkin Lymphoma, Relapsed Hodgkin's Disease, Adult, Refractory Hodgkin Lymphoma
Interventions
Nivolumab, Ipilimumab
Drug
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
4
States / cities
Chicago, Illinois • Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 16, 2026 · Synced Nov 2, 2026, 7:57 PM EST
Completed Phase 1 Interventional

BCX-1777 in Treating Patients With Refractory Cancer

NCT00073944
View directory record Official record
Conditions
Cancer
Interventions
forodesine hydrochloride
Drug
Lead sponsor
BioCryst Pharmaceuticals
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2003
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated May 30, 2013 · Synced Nov 2, 2026, 7:57 PM EST
Completed No phase listed Observational Accepts healthy volunteers

A Longitudinal Study of Effect of Copaxone in RRMS Over 24 Months

NCT01695434
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
MRI
Other
Lead sponsor
University at Buffalo
Other
Eligibility
18 Years to 65 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2013
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Mar 25, 2013 · Synced Nov 2, 2026, 7:57 PM EST
Terminated Phase 2 Interventional Results available

T-cell Depleted Alternative Donor Transplantation

NCT00968864
View directory record Official record
Conditions
Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Chronic Myeloid Leukemia, Myelodysplastic Syndrome, Lymphomas, Bone Marrow Failure, Hemoglobinopathy, Immune Deficiency, Osteopetrosis
Interventions
CliniMACS® (T cell depletion)
Device
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
Up to 30 Years
Enrollment
53 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2016
U.S. locations
1
States / cities
Charlotte, North Carolina
Source: ClinicalTrials.gov public record
Updated Apr 22, 2022 · Synced Nov 2, 2026, 7:57 PM EST
Active, not recruiting Phase 2Phase 3 Interventional

Long-Term Safety and Efficacy Evaluation of Amlitelimab in Participants of Previous Amlitelimab Moderate to Severe Atopic Dermatitis Clinical Trials

NCT05492578
View directory record Official record
Conditions
Dermatitis Atopic
Interventions
Amlitelimab, Topical corticosteroids, Topical calcineurin inhibitors, Oral corticosteroids
Drug
Lead sponsor
Sanofi
Industry
Eligibility
12 Years and older
Enrollment
1,856 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2029
U.S. locations
101
States / cities
Birmingham, Alabama • Scottsdale, Arizona • Tucson, Arizona + 77 more
Source: ClinicalTrials.gov public record
Updated Oct 13, 2026 · Synced Nov 2, 2026, 7:57 PM EST
Completed Phase 2 Interventional Results available

Phase 2, Randomized, Open-Label, Crossover, PD/PK Study of a Novel Pram-Insulin Co-Formulation in Adults With T1D

NCT04074317
View directory record Official record
Conditions
Diabetes Mellitus, Type 1, Insulin-dependent Diabetes Mellitus
Interventions
PRAM9, Regular Insulin + Pramlintide, Regular Insulin
Drug
Lead sponsor
Xeris Pharmaceuticals
Industry
Eligibility
18 Years to 64 Years
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Mar 27, 2024 · Synced Nov 2, 2026, 7:57 PM EST
Completed Phase 1 Interventional Accepts healthy volunteers

A Study of the Safety, Pharmacokinetics, and Pharmacodynamics of CNTO 3649 in Healthy Adults and Patients With Type 2 Diabetes Mellitus

NCT00882726
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
CNTO 3649 IV (Healthy participants), CNTO 3649 SC (Healthy participants), CNTO 3649 SC (Diabetic patients), Placebo
Drug
Lead sponsor
Centocor, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
133 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2010
U.S. locations
3
States / cities
Miramar, Florida • San Antonio, Texas • Tacoma, Washington
Source: ClinicalTrials.gov public record
Updated Dec 16, 2013 · Synced Nov 2, 2026, 7:57 PM EST
Completed Phase 3 Interventional Results available

Open Label, Phase III Study of NABI-IGIV 10% [Immune Globulin Intravenous(Human), 10%] In Subjects With Primary Immune Deficiency Disorders (PIDD)

NCT00538915
View directory record Official record
Conditions
Primary Immune Deficiency Disorders (PIDD)
Interventions
Nabi-IGIV 10% [Immune Globulin Intravenous (Human). 10%]
Biological
Lead sponsor
ADMA Biologics, Inc.
Industry
Eligibility
6 Years to 75 Years
Enrollment
63 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
17
States / cities
Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 13 more
Source: ClinicalTrials.gov public record
Updated Jul 30, 2021 · Synced Nov 2, 2026, 7:57 PM EST
Completed Phase 3 Interventional

A Comparison of 882C87 Versus Acyclovir in the Treatment of Herpes Zoster in Patients With Weakened Immune Systems

NCT00002315
View directory record Official record
Conditions
HIV Infections, Chickenpox
Interventions
Netivudine, Acyclovir
Drug
Lead sponsor
Glaxo Wellcome
Industry
Eligibility
18 Years and older
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
25
States / cities
Birmingham, Alabama • Tucson, Arizona • Los Angeles, California + 20 more
Source: ClinicalTrials.gov public record
Updated Jun 24, 2005 · Synced Nov 2, 2026, 7:57 PM EST
Completed Not applicable Interventional Results available

Reciprocating Medical Devices - a Study of a New Safety Device

NCT00651625
View directory record Official record
Conditions
Osteoarthritis, Rheumatoid Arthritis, Trauma, Thyroid Nodule, Cancer
Interventions
Reciprocating Procedure Device (RPD) - AVANCA Re No. 1091001, conventional syringe - BD Ref 309604
Device
Lead sponsor
University of New Mexico
Other
Eligibility
18 Years and older
Enrollment
437 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2010
U.S. locations
1
States / cities
Albuquerque, New Mexico
Source: ClinicalTrials.gov public record
Updated Mar 2, 2016 · Synced Nov 2, 2026, 7:57 PM EST
Completed Not applicable Interventional

Medications for Chronic HIV: Education and Collaboration

NCT01038076
View directory record Official record
Conditions
HIV Infections, Acquired Immunodeficiency Syndrome, Medication Adherence
Interventions
MedCHEC Tablet Computer & Adherence Care
Behavioral
Lead sponsor
Boston University
Other
Eligibility
18 Years and older
Enrollment
371 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2017
U.S. locations
3
States / cities
Los Angeles, California • Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Feb 20, 2018 · Synced Nov 2, 2026, 7:57 PM EST
Terminated Phase 2 Interventional Results available

Dose-ranging Study of Oral PHA-022121 for Prophylaxis Against Angioedema Attacks in Patients With Hereditary Angioedema Type I or Type II

NCT05047185
View directory record Official record
Conditions
Hereditary Angioedema, Hereditary Angioedema Type I, Hereditary Angioedema Type II, Hereditary Angioedema Types I and II, Hereditary Angioedema Attack, Hereditary Angioedema With C1 Esterase Inhibitor Deficiency, Hereditary Angioedema - Type 1, Hereditary Angioedema - Type 2, C1 Esterase Inhibitor Deficiency, C1 Inhibitor Deficiency
Interventions
Deucrictibant low dose, Deucrictibant high dose, Placebo
Drug
Lead sponsor
Pharvaris Netherlands B.V.
Industry
Eligibility
18 Years to 75 Years
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
3
States / cities
Birmingham, Alabama • Paradise Valley, Arizona • St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Aug 17, 2026 · Synced Nov 2, 2026, 7:57 PM EST
Completed No phase listed Observational

Study of People With HIV Infection Who Have High Viral Loads Despite Combination Antiretroviral Therapy

NCT01976715
View directory record Official record
Conditions
Acquired Immune Deficiency Syndrome Virus, Acquired Immunodeficiency Syndrome Virus, AIDS Virus, Human Immunodeficiency Virus, Human Immunodeficiency Viruses
Interventions
Not listed
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 100 Years
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2022
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 23, 2025 · Synced Nov 2, 2026, 7:57 PM EST
Terminated Phase 2 Interventional Results available

Retreatment Protocol for BL22 Immunotherapy in Relapsed or Refractory Hairy Cell Leukemia

NCT00924040
View directory record Official record
Conditions
Hairy Cell Leukemia
Interventions
BL22 (CAT-3888)
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 29, 2015 · Synced Nov 2, 2026, 7:57 PM EST